HELP

Cybin Inc.

HELP.US helus.com + Research + Basket
ISIN CA23256X4075
Employees 100
Phone 908 764 8385
Fiscal year end March
IPO Sep 13, 2019
Address 100 King Street West, Toronto, ON, Canada, M5X 1C9
10.56
-0.15 (-1.40%)
USD · NASDAQ
52-week range
3.76
15.15
Trading at 60% of the 52-week range
Market Cap
782.47M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
3.91
Div. Yield
N/A
% Institutions
41.98%
% Insiders
12.90%

1 Year

+43.2%

3 Year

-53.5%

10 Year

-78.6%
Description

Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders. The company's preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluate HLP003 for the adjunctive treatment of major depressive disorder; and Osmind for mental health treatments. It operates in Canada, the United States, the United Kingdom, and Ireland. The company was formerly known as Cybin Inc. and changed its name to Helus Pharma Inc. in October 2026. Helus Pharma Inc. was founded in 2019 and is headquartered in Toronto, Canada.

Actions

Add an action for HELP.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Mr. Greg Cavers Chief Financial Officer 1971
Mr. Aaron Bartlone Chief Operating Officer 1967
Dr. Amir Inamdar FFPM, MBBS Chief Medical Officer 1974
Mr. Michael I. Halstead J.D. CEO & Director 1973
Mr. John Kanakis Co-Founder 1980
Dr. Alex L. Nivorozhkin Ph.D. Chief Scientific Officer 1960
Ms. Lori Challenger Chief Compliance, Ethics & Administrative Officer NA
Mr. Gabriel Fahel Chief Legal Officer & Corporate Secretary 1976
Sara Brittany Somerset Chief Communications Officers NA
Ms. Regina Donohue Chief People Officer NA

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
VR Adviser, LLC 3.85M Jun 30, 2026 5.27% $0.77 0.00%
Orbimed Advisors LLC 3.27M Jun 30, 2026 4.48% $0.40 -14.65%
Adage Capital Partners Gp LLC 3.06M Jun 30, 2026 4.19% $0.03 337.14%
Millennium Management LLC 2.63M Jun 30, 2026 3.60% $0.01 8.95%
Rosalind Advisors, Inc. 1.96M Jun 30, 2026 2.68% $4.80 27.74%
Sphera Funds Management Ltd. 1.62M Jun 30, 2026 2.22% $1.40 64.20%
DCF Advisers, LLC 1.43M Jun 30, 2026 1.96% $1.68 107.37%
Sio Capital Management, LLC 1.30M Jun 30, 2026 1.78% $1.42 0.00%
Nan Fung Group Holdings Ltd 987.22K Jun 30, 2026 1.35% $4.96 114.61%
Boxer Capital Management, LLC 790.00K Jun 30, 2026 1.08% $0.39 23.44%
Logos Global Management LP 750.00K Jun 30, 2026 1.03% $0.21 0.00%
Citadel Advisors Llc 620.96K Jun 30, 2026 0.85% $0.00 -29.22%
Dafna Capital Management LLC 514.06K Jun 30, 2026 0.70% $0.65 3.15%
Walleye Trading Advisors, LLC 502.55K Jun 30, 2026 0.69% $0.01 0.00%
Morgan Stanley - Brokerage Accounts 461.89K Jun 30, 2026 0.63% $0.00 -54.95%
Knott David M Jr 370.00K Jun 30, 2026 0.51% $1.29 5.71%
Bank of America Corp 337.44K Jun 30, 2026 0.46% $0.00 0.00%
AdvisorShares Investments, LLC 292.71K Jun 30, 2026 0.40% $0.23 49.64%
Jane Street Group LLC 280.90K Jun 30, 2026 0.38% $0.00 164.13%
JPMorgan Chase & Co 237.83K Jun 30, 2026 0.33% $0.00 10,498.40%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Biotech Growth Ord 1.01M 1.38% ▲ 0.00% Jun 30, 2026
2 SEB Läkemedelsfond A (SEK) 884.74K 1.21% ▲ 15.84% Sep 30, 2026
3 AdvisorShares Psychedelics ETF 387.70K 0.53% ▲ 0.00% Sep 30, 2026
4 Royce Small-Cap Growth Growth Svc 281.00K 0.38% ▲ 21.12% Sep 30, 2026
5 Royce Small-Cap Trust 149.00K 0.20% ▲ 0.00% Sep 30, 2026
6 Fidelity Nasdaq Composite Index 77.28K 0.11% ▲ 383.28% Aug 31, 2026
7 Premier Miton Diversified GrB Inc 75.68K 0.10% ▲ 0.00% Aug 31, 2026
8 Fidelity Nasdaq Composite ETF 30.83K 0.04% ▲ 0.00% Sep 30, 2026
9 State Street® SPDR® S&P® Intl Sm Cp ETF 29.50K 0.04% ▲ 0.00% Sep 30, 2026
10 Premier Miton Global Leaders C Acc 27.31K 0.04% ▲ 0.00% Aug 31, 2026

Financial Highlights

▼
Market Cap: $782.47M
EBITDA: $-166.94M
Book Value: $3.91
Earnings/Share: $-4.15
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -44.38%
ROE (TTM): -86.94%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $736.40M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 73.06M
Shares Float: 58.10M
% Insiders: 12.90%
% Institutions: 41.98%
Shares Short: 3.01M
Shares Short (Prior Month): 3.46M
Short Ratio: 1.71

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$-44.68M
Cost of Goods Sold
adjust
$-119.23K
Gross Profit
subtotal
$-44.80M
SG&A
adjust
$-49.55M
R&D
adjust
$-86.04M
Operating Income
subtotal
$-141.68M
Other / Non-Operating Items
adjust
$-5.38M
Net Income
subtotal
$-147.05M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about HELP.US!